Fusion Antibodies (LON:FAB – Get Free Report) released its quarterly earnings results on Monday. The company reported GBX (1.20) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Fusion Antibodies had a negative return on equity of 210.32% and a negative net margin of 91.92%.
Fusion Antibodies Trading Down 12.0%
Shares of FAB stock opened at GBX 9.99 on Monday. The firm has a market cap of £12.50 million, a P/E ratio of -6.66 and a beta of 1.24. Fusion Antibodies has a 1-year low of GBX 9.10 and a 1-year high of GBX 21. The company has a debt-to-equity ratio of 92.42, a current ratio of 1.80 and a quick ratio of 2.36. The firm’s 50-day simple moving average is GBX 10.89 and its 200-day simple moving average is GBX 12.20.
About Fusion Antibodies
The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.
Read More
- Five stocks we like better than Fusion Antibodies
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Fusion Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
